Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF NASDAQ:ELAB NASDAQ:HEPA NASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$3.47-2.0%$3.49$2.83▼$23.40$2.27M1.09835,362 shs9,862 shsELABPMGC$2.04-5.8%$4.28$1.62▼$309.12$2.37M-0.275.33 million shs95,745 shsHEPAHepion Pharmaceuticals$0.06$0.05$0.03▼$0.10$686K1.5218,108 shs47,803 shsQLGNQualigen Therapeutics$1.44+1.4%$1.28$1.61▼$8.81$2.44M0.241.52 million shs39,479 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma+5.67%+10.97%+16.83%-14.90%-83.91%ELABPMGC+1.41%-12.20%-37.39%-79.55%-98.88%HEPAHepion Pharmaceuticals+35.75%-4.00%+15.16%+5.26%-84.54%QLGNQualigen Therapeutics+1.41%+2.92%+5.11%+5.11%-59.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$3.47-2.0%$3.49$2.83▼$23.40$2.27M1.09835,362 shs9,862 shsELABPMGC$2.04-5.8%$4.28$1.62▼$309.12$2.37M-0.275.33 million shs95,745 shsHEPAHepion Pharmaceuticals$0.06$0.05$0.03▼$0.10$686K1.5218,108 shs47,803 shsQLGNQualigen Therapeutics$1.44+1.4%$1.28$1.61▼$8.81$2.44M0.241.52 million shs39,479 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma+5.67%+10.97%+16.83%-14.90%-83.91%ELABPMGC+1.41%-12.20%-37.39%-79.55%-98.88%HEPAHepion Pharmaceuticals+35.75%-4.00%+15.16%+5.26%-84.54%QLGNQualigen Therapeutics+1.41%+2.92%+5.11%+5.11%-59.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 2.33Hold$65.001,774.28% UpsideELABPMGC 1.00SellN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/AQLGNQualigen Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$405K5.61N/AN/A$1.76 per share1.97ELABPMGC$590K4.00N/AN/A$93.33 per share0.02HEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AQLGNQualigen TherapeuticsN/AN/AN/AN/A($4.12) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$35.80N/AN/AN/AN/AN/AN/AN/AELABPMGC-$7.75M-$400.97N/AN/AN/AN/A-92.90%-67.56%N/AHEPAHepion Pharmaceuticals-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%5/12/2026 (Estimated)QLGNQualigen Therapeutics-$6.26M-$7.50N/AN/AN/AN/AN/A-202.16%5/19/2026 (Estimated)Latest HEPA, ELAB, QLGN, and CANF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026HEPAHepion Pharmaceuticals-$200.00N/AN/AN/AN/AN/A3/30/2026Q4 2025ELABPMGCN/A-$52.7570N/A-$52.7570N/A$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/AELABPMGC0.011.741.72HEPAHepion PharmaceuticalsN/A1.301.30QLGNQualigen TherapeuticsN/A0.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%ELABPMGC22.22%HEPAHepion Pharmaceuticals17.24%QLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%ELABPMGC0.14%HEPAHepion Pharmaceuticals0.06%QLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma8655,000N/ANot OptionableELABPMGC181.16 million1.16 millionN/AHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableHEPA, ELAB, QLGN, and CANF HeadlinesRecent News About These CompaniesQualigen Therapeutics (NASDAQ:QLGN) Trading Down 4.7% - Time to Sell?May 6 at 2:38 AM | americanbankingnews.comQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19December 13, 2025 | cnn.comQualigen Therapeutics Rebrands to AIxCrypto HoldingsNovember 17, 2025 | msn.comQualigen Therapeutics stockholders approve all proposals with majority voteNovember 17, 2025 | msn.comFaraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20November 16, 2025 | quiverquant.comQQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyNovember 16, 2025 | globenewswire.comQualigen Therapeutics to rebrand as AIxCryptoOctober 28, 2025 | msn.comQualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025October 27, 2025 | globenewswire.comQualigen Therapeutics partners with BitGo to execute C10 treasury allocationOctober 24, 2025 | msn.comQualigen Therapeutics stock surges after BitGo partnership for crypto treasuryOctober 24, 2025 | za.investing.comQualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto TreasuryOctober 24, 2025 | benzinga.comQualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury AllocationOctober 23, 2025 | globenewswire.comQualigen Therapeutics, Inc.: Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment ...October 14, 2025 | finanznachrichten.deQualigen Therapeutics, Inc. Launches C10 Cryptocurrency Asset Treasury Purchases Amid Crypto Market VolatilityOctober 12, 2025 | quiverquant.comQQualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?October 12, 2025 | globenewswire.comQualigen Therapeutics, Inc. Announces Leadership and Governance Changes to Support Strategic GrowthOctober 6, 2025 | quiverquant.comQQualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor TransitionOctober 6, 2025 | globenewswire.comUnivest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)September 30, 2025 | globenewswire.comQualigen Therapeutics stock soars after closing $41M PIPE financingSeptember 30, 2025 | investing.comQualigen Therapeutics closes $41M PIPE financing led by Faraday FutureSeptember 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEPA, ELAB, QLGN, and CANF Company DescriptionsCan-Fite BioPharma NYSE:CANF$3.47 -0.07 (-2.03%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.PMGC NASDAQ:ELAB$2.04 -0.13 (-5.79%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Hepion Pharmaceuticals NASDAQ:HEPA$0.06 0.00 (0.00%) As of 10:26 AM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Qualigen Therapeutics NASDAQ:QLGN$1.44 +0.02 (+1.41%) As of 05/6/2026Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
